Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor
Research article published in Current clinical pharmacology (2014)
Abstract
Anticoagulants have a key role in the management of venous and arterial thromboembolic disorders. Traditional anticoagulants, such as unfractionated heparin, low-molecular-weight heparins, fondaparinux, and vitamin K antagonists are effective but have limitations that make the management of thromboembolic disorders difficult. There is a clear need for new anticoagulants that are at least as effective as traditional agents but without their drawbacks. This review discusses the mechanism of action, pharmacokinetics, and pharmacodynamics of one of these newer agents - the direct Factor Xa inhibitor rivaroxaban - and provides an overview of the results of phase III clinical studies. Based on these results, rivaroxaban has gained approval for the prevention and treatment of several thromboembolic disorders in adult patients. Rivaroxaban, which has a rapid onset of action, targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex. It reaches maximal plasma concentration 2-4 hours after administration and has a high bioavailability (80-100%). Rivaroxaban has several advantages over traditional anticoagulants. It does not require dose adjustment for age, sex, body weight, or ethnicity, and there is no requirement for routine coagulation monitoring because it has been shown to have predictable pharmacokinetics and pharmacodynamics. Furthermore, rivaroxaban has minimal food and drug interactions. The introduction of newer oral anticoagulants, such as rivaroxaban, that are convenient to administer and have predictable pharmacokinetic and pharmacodynamic profiles, could ultimately simplify patient management in clinical practice and may improve clinical outcomes across a broad range of thromboembolic disorders.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed research on anticoagulant and antithrombotic drug development relevant to thrombin and factor inhibition. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta revisión describe el mecanismo de acción, la farmacocinética y la farmacodinámica del rivaroxabán, un inhibidor oral directo del Factor Xa, resumiendo que se dirige al Factor Xa libre y unido al coágulo y al Factor Xa en el complejo protrombinasa, alcanza la concentración plasmática máxima 2–4 horas después de la dosificación con una disponibilidad biológica de 80–100%, tiene una farmacocinética predecible que no requiere monitoreo de coagulación rutinario ni ajuste de dosis por edad, sexo, peso o etnia, y ha obtenido aprobación para varias indicaciones tromboembólicas en adultos basada en estudios de fase III. Su relevancia para la hirudoterapia es contextual: el rivaroxabán es un inhibidor sintético del Factor Xa, un blanco diferente y no una molécula derivada de lombriz, pero representa la clase de anticoagulantes orales modernos contra los que se comparan los inhibidores de trombina derivados del secretoma de lombriz en el panorama antitrombótico más amplio. Nota honesta: este es un resumen narrativo/revisión del perfil de un solo fármaco y resultados de fase III anteriores, no nuevos datos comparativos o de resultados, y no contiene contenido de lombriz medicinal, por lo que sirve como antecedentes del campo de los anticoagulantes en lugar de evidencia directa de hirudoterapia.
Citación
Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
Kreutz et al. · Current clinical pharmacology, 2014
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026